Hypothesis: The aim of this study was to determine the effects of renin-angiotensin system (RAS) blockade maintenance on renal protection in chronic kidney disease (CKD) patients with hyperkalemia occurring during treatment with RAS blockade. Materials and methods: CKD III or IV patients, who were prescribed with RAS blockers and also had hyperkalemia, were included. The study population was divided into two groups based on maintenance or withdrawal of RAS blocker. Renal outcomes (doubling of creatinine or end-stage renal disease) and incidence of hyperkalemia were compared between the two groups. Results: Out of 258 subjects who developed hyperkalemia during treatment with RAS blockers, 150 (58.1%) patients continued on RAS blockades, while RAS blockades were discontinued for more than 3 months in the remaining 108 patients. Renal event-free survival was significantly higher in the maintenance group compared with the withdrawal group. Cox proportional hazard ratio for renal outcomes was 1.35 (95% CI: 1.08-1.92, p=0.04) in the withdrawal group compared with the maintenance group. However, the incidence of hyperkalemia and hyperkalemia-related hospitalization or mortality did not differ between the two groups. Conclusions:This study demonstrated that the maintenance of RAS blockade is beneficial for the preservation of renal function and relatively tolerable in patients with CKD and hyperkalemia occurring during treatment with RAS blockade.
Introduction
The renin-angiotensin system (RAS) plays an important role in the pathogenesis and progression of chronic kidney disease (CKD). Numerous studies have reported that activation of the intra-renal RAS contributes to glomerular hypertrophy, mesangial expansion and glomerulosclerosis in various renal diseases. 1 Previous clinical and experimental studies have demonstrated that inhibition of the RAS using angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) results in the reduction of proteinuria and retards progression of renal disease in addition to lowering blood pressure. Even in normotensive or well-controlled hypertensive patients with CKD, use of RAS blockade resulted in reduction of proteinuria and may be beneficial in the preservation of renal function. [2] [3] [4] [5] [6] [7] [8] However, RAS blockade is frequently associated with several adverse events, including angioedema, dry cough, hyperkalemia, and aggravation of underlying renal insufficiency. 9 In particular, the incidence of hyperkalemia is increased in patients with reduced glomerular filtration rate (GFR) and limits the use of RAS blockade in patients with advanced CKD. 10 If the serum potassium level increases above 5.5 mmol/l during use of RAS blockade, discontinuation of RAS blockade should be considered, 11, 12 with hyperkalemia managed by, for example, prescription of a low-potassium diet, thiazide or loop diuretics, and correction of metabolic acidosis. However, there are different approaches to cope with RAS blockers according to physician preference and decision. A practical strategy for maintaining the RAS blockade is needed not only for control of blood pressure, but also to delay the progression of CKD. In order to maintain the blocking effect of RAS, ACEI or ARB are frequently maintained in CKD patients with elevated potassium levels. Still, it is not clear whether or not maintenance of RAS blockade is beneficial in CKD patients with elevated potassium levels.
We examined renal outcomes (doubling of creatinine or progression to end-stage renal disease (ESRD)) in order to determine the effect of RAS blockade maintenance in patients with CKD stage III and IV, who had developed hyperkalemia during use of RAS blockade. In addition, we evaluated the impact on hyperkalemia of maintenance with RAS blockade in this population.
Materials and methods
This study was approved by the Institutional Review Board (IRB) of Yonsei University Health System Clinical Trial Center. This study was a retrospective medical recordbased study and the IRB waived the requirement for written consent from the patients.
Study subjects
Patients with stage III or IV CKD, prescribed ACEI or ARB and with concurrent hyperkalemia during the use of RAS blockade were included in this study. We initially recruited 2124 patients who were followed-up for CKD at Yonsei University Health System from July 2008 to December 2011. ACEIs or ARBs except dual blockers including aldosterone antagonists were prescribed to 1239 patients, and 351 patients developed hyperkalemia during treatment with RAS blocker. Of these patients, 83 patients were excluded for the following reasons: age younger than 18 years or older than 75 years, terminal malignancy, previous history of kidney transplantation, and follow-up duration of less than 12 months. Patients whose serum creatinine and potassium levels at baseline or during the follow-up period were not available, or who were transiently discontinued RAS blockers for less than 3 months were also excluded. Therefore, a total of 258 patients were included for the final analysis ( Figure 1 ). 
Data collection
Using medical records, demographic and clinical data were reviewed retrospectively for age, sex, medical history, medications, time to doubling of baseline serum creatinine levels and ESRD, and history of admission after study enrollment. Laboratory data included urinary protein-tocreatinine ratio (UPCR), and serum creatinine and potassium levels. The four-variable Modification of Diet in Renal Disease study equation was used for calculation of the estimated glomerular filtration (eGFR).
Definitions
CKD was defined as an eGFR of less than 60 ml/min/1.73m 2 and hyperkalemia was defined as potassium ≥5.5 mmol/l in a non-hemolyzed serum sample. Patients with hyperkalemia that occurred after initiation of renal replacement treatment were not included. When hyperkalemia developed during treatment with RAS blockade, three kinds of clinical practice patterns were recognized contingent on the maintenance of RAS blockade: 1) discontinuation of RAS blockade; and 2) reduction or 3) maintenance of doses of RAS blockade with supportive management for potassium reduction. Patients were categorized as the maintenance group if they were maintained on RAS blockade without discontinuation of drugs, and as the withdrawal group if RAS blockade had been discontinued for >3 months after development of hyperkalemia. The criteria for maintenance of RAS blockers were not specified. Maintenance or withdrawal of RAS blockades were decided according to individual physicians.
Outcome endpoints
The main outcomes were a doubling of the baseline serum creatinine concentration and ESRD. ESRD was defined as initiation of renal replacement therapy including permanent hemodialysis, peritoneal dialysis or renal transplantation. In addition, incidence of hyperkalemia and hyperkalemiarelated hospitalization were also evaluated during the follow-up period.
Statistical analysis
SPSS, version 17.0 (SPSS Inc., Chicago, Illinois, USA) was used to perform statistical analysis. Continuous variables were expressed as mean ± standard deviation and categorical variables were expressed as percentages. T-test and chi-square test were used for comparison of the two groups. The Kolmogorov-Smirnov test was used for analysis of the normality of the distribution of parameters. Cumulative renal survival curves were derived using the Kaplan-Meier method, and differences between survival curves were compared using the log-rank test. Multivariate Cox proportional hazards models were used for determination of risk factors for renal outcomes. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the estimated regression coefficients and standard errors in the Cox regression analysis; a p-value <0.05 was considered statistically significant.
Results

Baseline characteristics
The baseline demographic, clinical and biochemical data of study subjects are shown in Table 1 . The mean age of patients was 61.8±14.5 years, and 145 patients (56%) were male. The mean eGFR and UPCR were 29.0±13.1 ml/ min/1.73m 2 and 2.3±3.0 mg/mg, respectively. Based on maintenance of RAS blocker, 150 (58.1%) of 258 patients were maintained on RAS blockades; however, 108 patients were discontinued for more than 3 months. Most of the patients in the maintenance group were maintained on the previous dose of RAS blockers, and the dose of RAS blockers was reduced in 41/150 patients (27.3%). There were no significant differences in underlying renal diseases, serum potassium levels, eGFR, or UPCR ratio at baseline between the two groups.
Renal outcomes
During a mean follow-up period of 45.7±18.3 months, 129 (50%) patients reached the primary outcome. ESRD or doubling of serum creatinine occurred in 68 (63%) patients in the withdrawal group compared with 61 (41%) patients in the maintenance group. Renal survival rate was significantly higher in the maintenance group compared with the withdrawal group (p=0.04, HR in the withdrawal group: 1.35, 95% CI: 1.08-1.92). In subgroup analysis based on the levels of baseline proteinuria, prognostic significance between two groups was much greater in subgroup of patients with UPCR above 1.0 (p=0.02, Figure 2 ). At baseline, serum creatinine levels were similar; however, after 18 months, serum creatinine levels were significantly lower in the maintenance group compared with the withdrawal group (p=0.03, Figure 3 ).
In multivariate Cox proportional hazard models, use of RAS blockers still remained a significant prognostic factor for renal survival. However, after adjusting for baseline proteinuria (HR; 1.028, p<0.01) and baseline GFR (HR; 1.248, p<0.01), the significance of RAS blocker maintenance as a predictor of renal progression disappeared (HR=1.135, CI; 0.937-1.546, p=0.17) ( Table 2 ).
Incidence of hyperkalemia and follow-up clinical outcomes
Baseline potassium levels were 5.79±0.38 mmol/l versus 5.77±0.48 mmol/l in the maintenance and withdrawal groups. During the follow-up period, 0.58 episodes per patient-year of hyperkalemia occurred in the maintenance group, and 0.47 episodes per patient-year developed in the withdrawal group (p=0. 19 ). In addition, neither hyperkalemia-related hospitalizations nor mortality differed between the two groups (0.18 episodes per patient-year vs. 0.14 episodes per patient-year, p=0.42). At the end of the study, potassium levels were 5.39±0.52 mmol/l versus 5.23±0.61 mmol/l in maintenance and withdrawal groups (p=0.14). Blood pressures at various time points during the follow-up period are listed in Table 3 . The blood pressures in the two groups were comparable during the follow-up period. During the follow-up period, 17 patients (11 patients in the maintenance group and six patients in the withdrawal group) died, and mortality rate was not different between two groups. One patient in each group died due to hyperkalemia-related events.
Discussion
This study demonstrated that maintenance of RAS blockade is beneficial for the preservation of renal function, even in hyperkalemic CKD patients treated with RAS blocker. In addition, cautious use of RAS blockade does not lead to a significant increase in the episodes of hyperkalemia in CKD patients who develop hyperkalemia during treatment with ACEI or ARB.
Based on previous reports, long-term blockade of the renin-angiotensin-aldosterone system by ACEIs or ARBs resulted in increased levels of plasma renin or angiotensin II. 13 In addition, occurrence of aldosterone breakthrough has been also reported during long-term ARB therapy, mainly by angiotensin II-dependent mechanisms. 14 Since renin or angiotensin II levels are already elevated in conditions of chronic blocking of the RAS, it is possible that renal failure and hypertension might be aggravated due to the abrupt disappearance of the RAS-blocking effect. Blocking of RAS might be maintained in order to prevent rebound hypertension and progression of renal failure. Our data support that maintenance of RAS blockade rather than withdrawal is beneficial for the preservation of renal function in CKD patients who have accompanying hyperkalemia during RAS blockade treatment.
The renoprotective effect of the RAS blocker was much more prominent in the subgroup with a baseline UPCR ratio of more than 1 mg/mg. This finding is consistent with previous studies, indicating an association of a higher urinary protein excretion rate with a rapid decline rate in renal function, 8 and ACEI has a distinguishable renoprotective effect in patients with baseline proteinuria of 3 g/day or more. 3 The present study suggests that maintenance of RAS blockade should be considered in highly proteinuric CKD patients.
In patients with CKD, development of hyperkalemia frequently occurs due to various causes such as reduced renal excretion of potassium or metabolic acidosis. [15] [16] [17] Besides discontinuation of RAS blockade, various approaches should be considered. Potassium imbalance might be treatable by restricting potassium intake and correction of underlying causes, while maintaining treatment with RAS blockade. A previous study showed that most of the patients with Data are expressed as n (%) or mean ± SD. eGFR: estimated glomerular filtration rate; UPCR: urine protein-to-creatinine ratio.
hyperkalemia were resolved with either a low-potassium diet alone or with dietary advice and decrease in dose of the ACEI. 18 Although the incidences of hyperkalemia after treatment with ACEI or ARB in patients with CKD were highly variable, clinical trials showed that prolonged use of RAS blockade did not lead to an increase in additional episodes of hyperkalemia in these patients. In addition, another study conducted in the CKD population reported no significant difference in the overall mortality rate among patients on ACEI/ARB therapy, compared with patients on placebo or conventional anti-hypertensive drugs. 3, 4, 7, 19 The present study also demonstrated that the incidence of hyperkalemia, as well as hyperkalemia-related hospitalization in study subjects, was similar in both groups whether or not RAS blockade had been maintained. Therefore, maintenance of the RAS blocker with careful monitoring, rather than only discontinuing RAS blockade, could be applied. This study has several limitations. Because its design is retrospective, this study may include sampling errors. There may be potential selection errors because maintenance of RAS blockade was decided by individual physicians. However, there are no specific guidelines and outcomes regarding whether use of RAS blocker is beneficial, due to a lack of appropriate guidelines. In addition, due to safety and ethical issues, it would be difficult to conduct a prospective study using RAS blockade in CKD patients who have hyperkalemia. Thus, in spite of the retrospective nature of the current study, we think that the study results are still valuable. Second, even though other drugs and conditions may have had an influence on serum potassium levels, these and dietary potassium intake were not evaluated. Therefore, further large-scale analysis is needed in order to confirm the risk and benefit of RAS blockade in this special population.
In conclusion, the renoprotective effects of RAS blockade in CKD patients with hyperkalemia disappeared after withdrawing RAS blockade. The results of the current study suggest that maintenance of RAS blockade retards the progression of renal failure, and these beneficial effects are more prominent in proteinuric CKD patients. In addition, ACEI/ARB is well tolerated in stage III or IV CKD patients with hyperkalemia occurring during treatment with RAS blockade. Values are expressed as mean ± SD. SBP: systolic blood pressure; DBP: diastolic blood pressure.
